73 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
, 2022. The decrease was primarily due to decreases of $7.3 million in direct research and development expenses mainly due to the completion of our … -related costs primarily due to the sublease of our East Grand facility, and $0.3 million in laboratory. Research and development expenses decreased by $4.5
424B3
UBX
Unity Biotechnology Inc
8 Dec 23
Prospectus supplement
4:39pm
;
our ongoing and planned clinical trials, including expectations with regard to the results of our clinical studies, preclinical studies and research … and development programs, including the timing and availability of data from such studies;
our predictions about the results of future or ongoing
8-K
EX-99.1
vqegfhdv7vnt rt
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
mir j9anmhu1ufdwj
8 Aug 23
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
4:04pm
8-K
EX-99.1
3bzv20h pvbzg3zt
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
ngpcgdyvioa md7
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
424B5
gbzcueuenvf7tztwv84
25 Oct 22
Prospectus supplement for primary offering
9:39pm
424B5
rw9dw90n2s 2nhoo66lf
19 Aug 22
Prospectus supplement for primary offering
8:42am
424B5
oeit993lpnea1
19 Aug 22
Prospectus supplement for primary offering
8:37am
424B5
dh1iv1p
16 Aug 22
Prospectus supplement for primary offering
5:26pm